bullish
Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow
568 Views25 Nov 2021 23:29
SUMMARY
- Pharmaessentia Corp (6446 TT) received FDA approval for its rare cancer drug, BESREMi, which has superior clinical efficacy over the existing standard of care.
- The drug has already been approved in 17 countries in EU, Taiwan, and South Korea. It is also being developed for several other indications, with license expected in next year.
- BESREMi’s continued success in the EU markets since its launch in 2019 has enhanced my conviction on the commercial accomplishment of BESREMi in the U.S.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Pharmaessentia Corp (6446 TT): Riding High Aided by Continued Strong Uptake of Besremi in US14 Nov 2022
- Pharmaessentia Corp (6446 TT): Key Marketed Drug Besremi Is Showing No Sign of Slow Down10 Aug 2022
- Pharmaessentia Corp (6446 TT): Key Drug Is Advancing Commercialization Globally05 May 2022
- Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow25 Nov 2021
x